Sofosbuvir/velpatasvir/voxilaprevir - Gilead Sciences

Drug Profile

Sofosbuvir/velpatasvir/voxilaprevir - Gilead Sciences

Alternative Names: GS 9857/sofosbuvir/velpatasvir; GS-5816/GS-9857/sofosbuvir; GS-7977/GS-5816/GS-9857; GS-9857/GS-5816/sofosbuvir; GS-9857/SOF/VEL; GS-9857/VEL/SOF; GS-9857/velpatasvir/sofosbuvir; SOF/GS-9857/VEL; SOF/VEL/GS-9857; SOF/VEL/VOX; Sofosbuvir/GS-5816/GS-9857; Sofosbuvir/GS-9857/velpatasvir; Sofosbuvir/velpatasvir/GS-9857; VEL/GS-9857/SOF; VEL/SOF/GS-9857; Velpatasvir/GS-9857/sofosbuvir; Velpatasvir/sofosbuvir/GS-9857; Vosevi

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 19 Mar 2018 Gilead Sciences completes a phase III trial for Hepatitis C (Treatment-experienced) in USA, Australia, Canada, France, Germany, New Zealand and United Kingdom (PO) (NCT03118843)
  • 16 Mar 2018 Registered for Hepatitis C (Treatment-experienced) in Australia (PO)
  • 20 Oct 2017 Adverse events data from a phase III trial in chronic hepatitis C infection presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top